Hikma Pharmaceuticals PLC - Board and Committee Changes

London, 24 February 2022 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (Hikma) announces the following changes to its board of directors and their responsibilities:

·      Dr. Pamela Kirby has decided not to stand for re-election at the next annual general meeting of the Company that is scheduled to take place on 25 April 2022; and

·      Nina Henderson will take over as chair of the Remuneration Committee with effect from the end of the annual general meeting.

Said Darwazah, Executive Chairman, said: 'I am very grateful to Pam for her leadership of the Remuneration Committee and the considerable value that she has added to the Board, particularly in relation to her expert knowledge of the pharmaceutical sector.  I wish Pam well for the future.  I am pleased that Nina has agreed to lead the Remuneration Committee going forward. Nina brings to the role a wealth of remuneration experience and a deep understanding of Hikma.'

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC

Peter Speirs, Company Secretary                                                                       +44 (0)20 7399 2772

Susan Ringdal, EVP Strategy and Global Affairs                                                 +44 (0)20 7399 2760

About Hikma

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

(LEI:549300BNS685UXH4JI75)